Evaluating BTK Inhibitors in CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

BTK Inhibitors in CLL On-Label and Off-Label Uses

RESONATE Ibrutinib in Previously Treated CLL

RESONATE Safety Profile of Ibrutinib in Previously Treated CLL

RESONATE-2 Ibrutinib in Previously Untreated CLL

Toxicities With Ibrutinib in RESONATE-2

In Vitro Off-Target Effects of Ibrutinib

Atrial Fibrillation and Ventricular Arrhythmias

Ibrutinib-Associated Bleeding Expert Observations and Suggestions

Ibrutinib-Associated Hypertension Expert Observations and Suggestions

Development of Ibrutinib Resistance

Acalabrutinib A Selective BTK Inhibitor

ACE-CL-001 Acalabrutinib in R/R CLL

Toxicities Associated With Acalabrutinib

Acalabrutinib in Ibrutinib-Intolerant Patients

Acalabrutinib in Front-Line CLL

Choosing Between BTK Inhibitors Guideline Recommendations and Expert Opinion

ELEVATE CLL R/R Acalabrutinib vs Ibrutinib in Previously Treated High-Risk CLL

Other Supportive Care Issues

Next-Generation BTK Inhibitors

Combination Approaches A Potential Pathway to Fixed-Duration Therapy?

Key Takeaways

Abbreviations

Abbreviations (cont)